The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
Peter ValkThe AML Global Portal were delighted to speak to Peter Valk, Erasmus University Medical Center, Rotterdam, NL, during the European School of Hematology (ESH) Translational Research Conference on AML. We asked Peter Valk: How do you integrate molecular diagnostics in clinical practice?
Peter Valk discusses the role of Next Generation Sequencing (NGS) in clinical decision- making in AML. He explains the important role of NGS in routine molecular-based diagnostics, prognostic and response monitoring such as measuring the presence or absence of whole genes and monitoring somatic and germline mutations.
How do you integrate molecular diagnostics in clinical practice?